Campbell Bradley L 4

What Happened

• Bradley L. Campbell (President & CEO, Director) disposed of equity interests tied to Amicus Therapeutics' acquisition by BioMarin Pharmaceutical. The Form 4 shows 1,008,680 shares disposed at $14.50/share for $14,625,860, plus multiple derivative dispositions (options/RSUs) that were cashed out or vested in connection with the Merger.
• In total, the reported dispositions cover approximately 2,973,089 shares worth of equity/derivative instruments. The 1,008,680-share component produced the stated cash payment; the option-related disposals were converted to cash payments based on the merger price less each option’s exercise price (exact cash amounts for those conversions are not listed).

Key Details

• Transaction date and filing date: 2026-04-27 (filed same day — appears timely).
• Price reported for common shares: $14.50 per share; cash received for that line: $14,625,860. Derivative lines list N/A price because options were cancelled and converted into cash consideration per the merger terms.
• Total disposed (aggregate of common + derivative units): ~2,973,089 shares (includes 689,467 common stock and 319,213 RSUs noted in footnote F1).
• Footnotes of note:
  • F1: Some shares were RSUs that vested at closing (319,213 RSUs) and were disposed in the transaction.
  • F2–F4: Each reported stock option was fully vested and was cancelled and converted into a cash payment equal to (14.50 − option exercise price) × number of underlying shares.
• Shares owned after the transaction: not specified in the provided summary (see full Form 4 for post-transaction holdings).
• No 10b5-1 plan or gifting/tax-withholding notes reported in the provided details.

Context

• These were corporate-transaction dispositions (disposition to issuer) tied to the merger consideration, not open-market sales. For the options, “disposed” means the options were cashed out (not exercised to retain shares) — the company paid cash for the option value based on the merger price.
• Such filings in an M&A context are routine: RSUs commonly vest at closing and in-the-money options are often cancelled for cash consideration. This does not, by itself, indicate management sentiment about the company’s future independent of the merger terms.